Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Genetic Influence for Obesity Linked to a Baker’s Dozen

The impact that our genetic background has on daily metabolism cannot be overstated, as a team of investigators has just discovered that variations within 13 genes can have a considerable influence on how easily an individual can gain or lose weight. This larg

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The impact that our genetic background has on daily metabolism cannot be overstated, as a team of investigators has just discovered that variations within 13 genes can have a considerable influence on how easily an individual can gain or lose weight. This large-scale genome-wide association study (GWAS), overseen by the Genetic Investigation of Anthropometric Traits (GIANT) consortium, is the first to pinpoint genetic variations that may directly impact the function of genes associated with body mass index (BMI). Findings from the study were published recently in Nature Genetics in an article entitled “Protein-Altering Variants Associated with Body Mass Index Implicate Pathways That Control Energy Intake and Expenditure in Obesity.”

“Our study has identified genes that play a crucial role in the neuronal control of body weight. They act in the brain in pathways that may affect people's food intake, hunger, satiety, etc.,” explained senior study investigator Ruth Loos, Ph.D., a professor at The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai. “Individuals who inherit these genetic variations may find it harder to eat less or stop eating, as compared to those who did not inherit these variations. It is also the first time a genetic association study for BMI identifies genes that act in pathways that affect energy expenditure and fat cell biology.”

Over the past decade, researchers in the GIANT consortium have performed GWAS in hundreds of thousands of individuals to identify genetic variations associated with obesity and BMI. However, until now, the genetic variations they identified were mere “flags” on the genome that highlighted DNA sequences of interest. In this new study, however, the consortium focused on a specific set of genetic variations that are likely to affect the function of genes and their proteins—an approach that expedited the discovery of the causal genes that affect body weight.

The study was an international collaboration involving more than 250 research institutions. Genetic data from more than 700,000 individuals and 125 different studies was combined to form the largest genetic association study to date. The researchers identified 14 genetic variations in 13 genes, including a risky copy variation—a phenomenon in which sections of the genome are repeated—that causes carriers to weigh 15 pounds more, on average, than individuals who do not carry the variation. The gene is called MC4R, and approximately 1 in 5000 individuals carry this risk copy, which causes the gene not to produce any of the protein needed to inform the brain to stop eating.

Interestingly, while this variant was identified two decades ago in individuals with extreme and early-onset obesity, the new study shows that it also affects body weight in the general population. Moreover, the researchers identified two variants that may affect the function of a gene called GIPR. Approximately 1 in 400 individuals carry a protective copy of either variant, and they tend to weigh an average of 4.5 pounds less than noncarriers. Eight of the 13 genes identified were newly implicated in obesity and will require further follow-up to understand the mechanisms through which they affect body weight.

“By considering the genes as a group rather than one-by-one, we could highlight specific genes that both had strong support from genetics and that likely carry out functions that we predict to be important in controlling body weight,” said Joel Hirschhorn, M.D., Ph.D., Concordia Professor of Pediatrics and Professor of Genetics at Boston Children's Hospital and Harvard Medical School, co-director of the Metabolism Program at the Broad Institute and the GIANT consortium.

By knowing the genes and the biological pathways through which they work, researchers believe they are a few steps closer to understanding why some people gain weight more easily than others, which is critical for developing effective treatments.

“Our study has provided new potential targets for therapeutic interventions, and may even help personalize treatment for carriers of the genetic variations,” Dr. Loos concluded. “While we are a few steps closer to understanding the biology of why some people gain or lose weight more easily than others, further research on each of the identified genes is needed to understand the mechanisms through which they act.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →